SCHEMBL5135903

SCHEMBL5135903

CCCCN(Cc1ccc(CC)cc1)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CC

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.41
CRHR1 P34998 2/20 0.41
ATP4A P20648 4/20 0.39
ATP4B P51164 4/20 0.39
BCHE P06276 1/20 0.38
HDAC1 Q13547 1/20 0.37
MAPT P10636 1/20 0.37
TSHR P16473 2/20 0.36
HSD11B1 P28845 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP3A4 P08684 1/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136089 0.93 CRHR1 (0.43) C5AR1CRHR1ATP4AATP4BBCHE
SCHEMBL5072249 0.92 C5AR1 (0.47) C5AR1CRHR1ATP4AATP4BBCHE
SCHEMBL5135456 0.92 C5AR1 (0.43) C5AR1CRHR1ATP4AATP4BBCHE
SCHEMBL5134917 0.91 C5AR1 (0.44) C5AR1CRHR1ATP4AATP4BTSHR
SCHEMBL5075018 0.89 CRHR1 (0.40) C5AR1CRHR1ATP4AATP4BBCHE
SCHEMBL5135000 0.89 ATP4A (0.47) ATP4AATP4BBCHE
SCHEMBL5135106 0.88 C5AR1 (0.47) C5AR1CRHR1TSHRHSD11B1KDM4E
SCHEMBL5136290 0.88 HSD11B1 (0.42) C5AR1CRHR1ATP4AATP4BBCHE
SCHEMBL5136847 0.87 MAPT (0.44) C5AR1CRHR1ATP4AATP4BBCHE
SCHEMBL5137489 0.87 C5AR1 (0.48) C5AR1CRHR1ATP4AATP4BTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed